Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Aquestive therapeutics, inc. save search
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
Published: 2022-03-17 (Crawled : 13:00) - biospace.com/
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 8.57%
H: 4.1%
C: 1.63%
aqst-109 fast track designation react treatment fda fast track therapeutics fda fast track merge designation
Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China
Published: 2022-03-03 (Crawled : 14:00) - biospace.com/
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 5.54%
H: 4.59%
C: -0.33%
treatment als therapeutics china group license riluzole
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi
Published: 2021-10-25 (Crawled : 13:00) - aquestive.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions
Published: 2021-10-25 (Crawled : 13:00) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 1.64%
H: 9.45%
C: 7.6%
treatment epinephrine phase 1 positive topline drug trial merge
Mitsubishi Tanabe Pharma America Announces EXSERVAN™ (riluzole) is Now Available in the U.S. for the Treatment of ALS
Published: 2021-06-30 (Crawled : 18:00) - biospace.com/
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: -0.25%
H: 0.25%
C: -0.75%
treatment als riluzole pharma
Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment
Published: 2021-01-21 (Crawled : 22:00) - biospace.com/
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 1.28%
H: 4.5%
C: 1.26%
treatment license als riluzole pharma
Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
Published: 2020-06-29 (Crawled : 09:08) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 1.79%
H: 0.66%
C: -1.95%
liver trial treatment
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis
Published: 2020-08-10 (Crawled : 09:08) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 2.23%
H: 10.58%
C: 8.09%
fda liver treatment fast track fda fast track fast track designation designation
Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis
Published: 2020-08-20 (Crawled : 09:08) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 0.24%
H: 8.88%
C: 4.44%
liver trial treatment phase 3 phase 1 phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.